Capital International Sarl Purchases 5,237 Shares of NovoCure Limited (NASDAQ:NVCR)

Capital International Sarl lifted its position in shares of NovoCure Limited (NASDAQ:NVCRGet Rating) by 11.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 51,581 shares of the medical equipment provider’s stock after purchasing an additional 5,237 shares during the period. Capital International Sarl’s holdings in NovoCure were worth $4,273,000 at the end of the most recent quarter.

A number of other large investors also recently made changes to their positions in the company. Capital International Ltd. CA increased its holdings in NovoCure by 8.5% during the first quarter. Capital International Ltd. CA now owns 106,902 shares of the medical equipment provider’s stock worth $8,857,000 after buying an additional 8,362 shares during the last quarter. Wealthfront Advisers LLC purchased a new stake in NovoCure during the first quarter worth about $220,000. Donoghue Forlines LLC increased its holdings in NovoCure by 43.6% during the first quarter. Donoghue Forlines LLC now owns 8,708 shares of the medical equipment provider’s stock worth $721,000 after buying an additional 2,643 shares during the last quarter. Eaton Vance Management increased its holdings in NovoCure by 146.1% during the first quarter. Eaton Vance Management now owns 34,715 shares of the medical equipment provider’s stock worth $2,876,000 after buying an additional 20,611 shares during the last quarter. Finally, Guggenheim Capital LLC purchased a new stake in NovoCure during the first quarter worth about $1,194,000. 76.45% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on NVCR. Piper Sandler decreased their price objective on shares of NovoCure from $100.00 to $90.00 in a report on Thursday, July 28th. Evercore ISI downgraded shares of NovoCure from an “in-line” rating to an “underperform” rating and set a $55.00 target price for the company. in a research note on Tuesday, July 5th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $107.57.

NovoCure Price Performance

Shares of NASDAQ:NVCR opened at $88.06 on Thursday. The company has a 50 day moving average of $78.05 and a 200 day moving average of $76.36. The stock has a market cap of $9.22 billion, a P/E ratio of -135.48 and a beta of 0.79. NovoCure Limited has a 12 month low of $56.39 and a 12 month high of $132.38. The company has a current ratio of 8.08, a quick ratio of 7.87 and a debt-to-equity ratio of 1.28.

NovoCure (NASDAQ:NVCRGet Rating) last issued its quarterly earnings data on Thursday, July 28th. The medical equipment provider reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.09). The firm had revenue of $140.90 million for the quarter, compared to analysts’ expectations of $135.13 million. NovoCure had a negative net margin of 12.52% and a negative return on equity of 16.04%. NovoCure’s revenue was up 5.5% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.14) EPS. As a group, sell-side analysts forecast that NovoCure Limited will post -0.89 EPS for the current fiscal year.

Insider Buying and Selling at NovoCure

In other NovoCure news, Chairman William F. Doyle sold 837 shares of NovoCure stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $69.66, for a total transaction of $58,305.42. Following the completion of the sale, the chairman now directly owns 551,176 shares in the company, valued at $38,394,920.16. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, insider Ely Benaim sold 437 shares of the business’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $69.66, for a total value of $30,441.42. Following the completion of the sale, the insider now directly owns 34,631 shares in the company, valued at approximately $2,412,395.46. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman William F. Doyle sold 837 shares of NovoCure stock in a transaction on Tuesday, August 2nd. The stock was sold at an average price of $69.66, for a total transaction of $58,305.42. Following the completion of the transaction, the chairman now directly owns 551,176 shares in the company, valued at $38,394,920.16. The disclosure for this sale can be found here. Insiders sold a total of 3,137 shares of company stock worth $252,691 over the last three months. 6.22% of the stock is owned by insiders.

NovoCure Profile

(Get Rating)

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma.

Featured Articles

Institutional Ownership by Quarter for NovoCure (NASDAQ:NVCR)

Receive News & Ratings for NovoCure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovoCure and related companies with MarketBeat.com's FREE daily email newsletter.